Literature DB >> 28921280

Comparison of postoperative liver dysfunction following halothane and sevoflurane anesthesia in women undergoing mastectomy for cancer.

Saburo Tsujimoto1, Hiroko Kato1, Yukiko Minamoto1, Hideaki Miki2, Rie Kitamura2.   

Abstract

The incidence of an abnormal increase in the serum levels of glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) following anesthesia with halothane and 65% nitrous oxide in oxygen (halothane group) or with sevoflurane and 65% nitrous oxide in oxygen (sevoflurane group) was compared in women undergoing surgery for breast cancer. An abnormal increase in GOT and GPT, both defined as higher than 50 IU, occurred postoperatively in 2 of the 150 patients (1.7%) in the sevoflurane group, and in 37 of the 200 (18.5%) in the halothane group (P<0.001). The elevated levels of serum transaminases after sevoflurane ranged from 50 to 65 IU whereas those after halothane ranged from 50 to 1000 IU, except for a value greater than 5000 IU in 1 patient. In the halothane group, there was a significant association between postoperative increases in serum transaminases and previous exposure to inhalation anesthetics, postoperative mitomycin therapy, and radiation therapy (all P<0.001). The results of multivariate analysis, when data from all patients were taken together, showed that the type of anesthetic (halothane) was the highest factor related to postoperative increases in GOT and GPT (odds ratio 35.85; 95% confidence interval 5.92-217.37), followed next by prior exposure to inhalation anesthetics (8.65; 2.96-25.27), postoperative radiation therapy (4.37; 1.70-11.19), and postoperative mitomycin therapy (3.56; 1.23-10.35). These data suggest that sevoflurane is less likely to cause anesthesia-related liver dysfunction than halothane.

Entities:  

Keywords:  Halothane; Liver function; Sevoflurane; Transaminases

Year:  1995        PMID: 28921280     DOI: 10.1007/BF02479843

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  18 in total

1.  Clinical evaluation and metabolism of sevoflurane in patients.

Authors:  H Kikuchi; M Morio; K Fujii; K Mukaida; M Horibe; T I Davidkova; S Kawachi; N Sato
Journal:  Hiroshima J Med Sci       Date:  1987-03

2.  [Hepatic effects of sevoflurane--changes in the drug-metabolizing enzyme and morphologic features].

Authors:  S Miyoshi
Journal:  Masui       Date:  1988-04

Review 3.  Hepatotoxicity of volatile anaesthetics.

Authors:  R H Elliott; L Strunin
Journal:  Br J Anaesth       Date:  1993-03       Impact factor: 9.166

4.  [A case of suspected liver dysfunction induced by sevoflurane anesthesia].

Authors:  K Watanabe; S Hatakenaka; K Ikemune; Y Chigyo; T Kubozono; T Arai
Journal:  Masui       Date:  1993-06

Review 5.  Halothane anaesthesia and liver damage.

Authors:  J Neuberger; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-27

6.  [A case of postoperative hepatic injury after sevoflurane anesthesia].

Authors:  Y Shichinohe; Y Masuda; H Takahashi; M Kotaki; T Omote; M Shichinohe; A Namiki
Journal:  Masui       Date:  1992-11

7.  A prospective study of liver enzyme and other changes following repeat administration of halothane and enflurane.

Authors:  J P Fee; G W Black; J W Dundee; P D McIlroy; H M Johnston; S B Johnston; I H Black; H G McNeill; D W Neill; J R Doggart; J D Merrett; J R McDonald; D S Bradley; M Haire; S A McMillan
Journal:  Br J Anaesth       Date:  1979-12       Impact factor: 9.166

8.  Controlled trial of repeated halothane anaesthetics in patients with carcinoma of the uterine cervix treated with radium.

Authors:  J Trowell; R Peto; A C Smith
Journal:  Lancet       Date:  1975-04-12       Impact factor: 79.321

9.  Controlled prospective study of the effect on liver function of multiple exposures to halothane.

Authors:  R Wright; O E Eade; M Chisholm; M Hawksley; B Lloyd; T M Moles; J C Edwards; M J GArdner
Journal:  Lancet       Date:  1975-04-12       Impact factor: 79.321

10.  Clinical characteristics and biotransformation of sevoflurane in healthy human volunteers.

Authors:  D A Holaday; F R Smith
Journal:  Anesthesiology       Date:  1981-02       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.